DMK Pharmaceuticals Q3 EPS $(0.20) Up From $(2.05) YoY, Sales $9.06K Down From $1.51M YoY
Portfolio Pulse from Benzinga Newsdesk
DMK Pharmaceuticals (NASDAQ:DMK) reported a significant improvement in Q3 EPS to $(0.20) from $(2.05) YoY, but sales plummeted to $9.06K from $1.51M YoY, indicating a 99.40% decrease.
November 14, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DMK Pharmaceuticals reported a smaller loss per share in Q3 compared to last year, but sales saw a drastic decline.
While the improvement in EPS might be seen as a positive development, the dramatic decrease in sales is likely to concern investors and could negatively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100